Mar 15, 2019 by Brian Orelli, PhDHere's Why Diplomat Pharmacy Stock Fell 13.6% Today2019 will be a rebuilding year for the specialty pharmacy.
Mar 13, 2019 by Brian Orelli, PhDHere's Why Sientra Stock Is Plummeting TodayInvestors are worried about the aesthetics company's profitability.
Mar 4, 2019 by Brian Orelli, PhDIonis Pharmaceuticals Funds Its Pipeline of More Than 40 DrugsThe biotech turned an operating profit in the fourth quarter thanks to revenue from partners.
Mar 1, 2019 by Brian Orelli, PhDHere's Why Castlight Health Jumped 24% on FridayThe health-navigation platform company produced its first cash-flow-positive quarter.
Feb 28, 2019 by Brian Orelli, PhDHere's Why Syneos Health Plummeted TodayThe biopharmaceutical solutions company is under investigation by the SEC.
Feb 28, 2019 by Brian Orelli, PhDMomenta Continues to RebuildThe biotech is waiting for proof-of-concept data expected next year.
Feb 27, 2019 by Brian Orelli, PhDHere's Why Ionis Pharmaceuticals Jumped Higher TodayFourth-quarter earnings exceed expectations.
Feb 26, 2019 by Brian Orelli, PhDWith a Stocked War Chest, bluebird bio Presses OnThe biotech is on the verge of its first approval, with three more in the works.
Feb 26, 2019 by Brian Orelli, PhDBioMarin Revenue Slips, but Big Picture Looks DandyLumpy sales hurt the orphan-drug maker's fourth quarter, but overall growth is still on track.
Feb 25, 2019 by Brian Orelli, PhDEmergent BioSolutions Looks to Break $1 BillionNewly acquired products should help the bioterrorism specialist hit its goal.
Feb 25, 2019 by Brian Orelli, PhDHere's Why Clementia Pharmaceuticals Rocketed Higher TodayThe Canadian biotech is being acquired.
Feb 21, 2019 by Brian Orelli, PhDGenomic Health Continues Its Profitable WaysThe cancer test maker is growing earnings much faster than revenue.
Feb 21, 2019 by Brian Orelli, PhD$35 Billion Market! Positive Clinical Trial! Yet Shares Are Down?Here are four reasons Intercept stock is down despite positive data in the company's NASH trial.
Feb 15, 2019 by Brian Orelli, PhDNatus Has Some Growing Up to Do2019 will be a rebuilding year for the neurology and newborn-care specialist.
Feb 13, 2019 by Brian Orelli, PhDExelixis Grabs 90% of First PlaceIn a multibillion dollar cancer-treatment market, a solid second isn't too shabby.
Feb 12, 2019 by Brian Orelli, PhDImmunoGen Still Waiting to Take Its Leap "Forward"Data from a late-stage clinical trial is expected in the first half of this year.
Feb 12, 2019 by Brian Orelli, PhDAlnylam Pharmaceuticals Is Launched and Ready for MoreThe biotech has launched its first drug, Onpattro, but don't forget about its pipeline of drugs to come.
Feb 11, 2019 by Brian Orelli, PhDBard Helps Becton, Dickinson Continue SingingFour quarters into the integration, Bard continues to drive top- and bottom-line growth at the combined healthcare company.
Feb 8, 2019 by Brian Orelli, PhDSeattle Genetics Looks to Make Adcertis a Blockbuster; Investors UnimpressedWith shares up 30% year to date, investors may be taking profits.
